7. 7
อ้างอิง
1. Balog J. National health insurance in America--the issue of copayment. West J Med.
1990;152(1):76.
2. OECD, OECD health Statistics 2014: How does the United Sates compare?,
https://www.oecd.org/unitedstates/Briefing-Note-UNITED-STATES-2014.pdf
3. Bae SJ, Paltiel AD, Fuhlbrigge AL, Weiss ST, Kuntz KM. Modeling the potential impact
of a prescription drug copayment increase on the adult asthmatic medicaid
population. Value Health. 2008;11(1):110-8.
4. Fischer PJ, Strobino DM, Pinckney CA. Utilization of child health clinics following
introduction of a copayment. Am J Public Health. 1984;74(12):1401-3.
5. Joyce GF. Understanding Primary Nonadherence. Am J Pharm Benefits. 2010;2(2):111-
8.
6. Linnet K, Halldorsson M, Thengilsdottir G, Einarsson OB, Jonsson K, Almarsdottir AB.
Primary non-adherence to prescribed medication in general practice: lack of
influence of moderate increases in patient copayment. Fam Pract. 2013;30(1):69-75.
7. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate
greater medication adherence in targeted patients. Health Aff (Millwood).
2010;29(11):2002-8.
8. Maciejewski ML, Yancy WS, Jr., Olsen M, Weidenbacher HJ, Abbott D, Weinberger M,
et al. Demand for weight loss counseling after copayment elimination. Prev Chronic
Dis. 2013;10:E49.
9. Parente ST, Evans WN. Effect of Low-Income Elderly Insurance Copayment Subsidies.
Health Care Financ Rev. 1998;20(2):19-37.
10. Puig-Junoy J, Rodriguez-Feijoo S, Gonzalez Lopez-Valcarcel B, Gomez-Navarro V.
[Impact of the Pharmaceutical Copayment Reform on the Use of Antidiabetics,
Antithrombotics and for Chronic Obstructive Airway Disease Agents, Spain]. Rev Esp
Salud Publica. 2016;90:E6.